Argent BioPharma Eyes Strategic Delisting Move

Argent Biopharma (AU:RGT) has released an update.

Argent BioPharma Ltd., a biopharmaceutical company specializing in drug discovery, has announced an upcoming shareholder vote on its potential delisting from the Australian Securities Exchange (ASX). The vote will take place on October 1, 2024, and is contingent on the approval of a category transfer on the Financial Conduct Authority’s Official List, which would require meeting certain prerequisites and the appointment of a Sponsor. The company emphasizes there is no certainty the delisting or the transfer to the London Stock Exchange’s equity shares category will occur without fulfilling these conditions.

For further insights into AU:RGT stock, check out TipRanks’ Stock Analysis page.